Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Eledon Pharmaceuticals ( (ELDN) ).
On June 10, 2025, Eledon Pharmaceuticals, Inc. held its Annual Meeting of Stockholders, where four key proposals were voted on. The stockholders elected three Class II Directors for a term ending in 2028, approved amendments to increase authorized shares and provide exculpation for certain officers, and ratified Deloitte & Touche LLP as the independent accounting firm for 2025.
The most recent analyst rating on (ELDN) stock is a Buy with a $20.50 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.
Spark’s Take on ELDN Stock
According to Spark, TipRanks’ AI Analyst, ELDN is a Underperform.
Eldon Pharmaceuticals faces significant financial challenges with a lack of revenue and persistent losses, reflected in its low financial performance score. The stock’s technical indicators point towards a bearish trend, further compounded by a negative P/E ratio and no dividend yield. The company’s future hinges on successful product development or strategic financial interventions to improve its financial and market position.
To see Spark’s full report on ELDN stock, click here.
More about Eledon Pharmaceuticals
Average Trading Volume: 214,036
Technical Sentiment Signal: Sell
Current Market Cap: $179M
Find detailed analytics on ELDN stock on TipRanks’ Stock Analysis page.